Department of Vitreoretina, Dr. Shroff's Charity Eye Hospital, New Delhi, India.
Department of Anesthesia, Dr. Shroff's Charity Eye Hospital, New Delhi, India.
Indian J Ophthalmol. 2019 May;67(5):636-640. doi: 10.4103/ijo.IJO_1386_18.
We conducted a prospective, randomized study to evaluate the efficacy of dexmedetomidine as an additive to peribulbar block for vitreoretinal surgery in terms of onset time of block, hemodynamic stability profile, patient comfort, and surgeon satisfaction.
One hundred patients of American Society of Anesthesiologists grade 1 and 2 scheduled for vitreoretinal surgery were randomly assigned into two groups: control group (n = 50) received lignocaine bupivacaine block, and Dex group (n = 50) received lignocaine bupivacaine plus 20 μg dexmedetomidine peribulbar block. Information regarding time for onset of block, hemodynamic data, visual analog scale for pain, sedation levels, total duration of surgery, and surgeon satisfaction levels were collected.
All the demographic characteristics including age, gender, American Society of Anesthesiologists grade, onset of anesthesia, and duration of surgery were comparable in both groups. At the baseline, there was no statistically significant difference in heart rate, mean arterial pressure, diastolic blood pressure, and respiratory rate between the two groups, with a difference noted in systolic blood pressure at the baseline. There was significant difference noted in the systolic blood pressure and mean arterial pressure at different time intervals with a decreasing trend as time progressed. The mean sedation score was significantly higher in the Dex group than that in the control group. The surgeon satisfaction was higher in the Dex group than that in the control group.
Dexmedetomidine is a useful and safe drug in combination with lignocaine bupivacaine in peribulbar for vitreoretinal surgery as it maintains hemodynamic stability and provides sedation, which enables full cooperation and potentially better operating conditions.
我们进行了一项前瞻性、随机研究,评估右美托咪定作为一种添加剂用于球周阻滞在阻滞起效时间、血流动力学稳定性、患者舒适度和术者满意度方面对玻璃体视网膜手术的效果。
100 例美国麻醉医师协会(ASA)分级 1 和 2 的玻璃体视网膜手术患者被随机分为两组:对照组(n=50)接受利多卡因布比卡因阻滞,Dex 组(n=50)接受利多卡因布比卡因加 20μg 右美托咪定球周阻滞。收集阻滞起效时间、血流动力学数据、疼痛视觉模拟评分、镇静水平、手术总持续时间和术者满意度等信息。
两组的所有人口统计学特征,包括年龄、性别、ASA 分级、麻醉开始时间和手术持续时间均相似。在基线时,两组间心率、平均动脉压、舒张压和呼吸频率无统计学差异,而收缩压在基线时有差异。不同时间点的收缩压和平均动脉压均有显著差异,随时间推移呈下降趋势。Dex 组的平均镇静评分明显高于对照组。Dex 组的术者满意度明显高于对照组。
右美托咪定与利多卡因布比卡因联合用于球周阻滞对玻璃体视网膜手术是一种有用且安全的药物,因为它能维持血流动力学稳定并提供镇静作用,从而使患者能够充分合作并提供更好的手术条件。